(Q38193861)

30 August 2017

1 reference

title

Defining severity in non-cystic fibrosis bronchiectasis (English)

1 reference

30 August 2017

0 references

1 reference

2

James D Chalmers

1 reference

30 August 2017

Lucy Poppelwell

1

1 reference

30 August 2017

publication date

1 April 2014

1 reference

Expert Review of Respiratory Medicine

30 August 2017

published in

1 reference

30 August 2017

volume

8

1 reference

30 August 2017

issue

2

1 reference

30 August 2017

page(s)

249-262

1 reference

Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Research priorities in bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Increasing outpatient treatment of mild community-acquired pneumonia: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Mortality in bronchiectasis: a long-term study assessing the factors influencing survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Analysis of the factors related to mortality in patients with bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Bronchiectasis-associated hospitalizations in Germany, 2005-2011: a population-based study of disease burden and trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Socioeconomic deprivation, readmissions, mortality and acute exacerbations of bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Quality-of-life determinants in patients with clinically stable bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Evaluating cough assessment tools: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

A comparison of serial computed tomography and functional change in bronchiectasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Decreased survival in patients with co-existent rheumatoid arthritis and bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Airflow obstruction in bronchiectasis: correlation between computed tomography features and pulmonary function tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

High-resolution computed tomography in young patients with cystic fibrosis: distribution of abnormalities and correlation with pulmonary function tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Spirometer-triggered high-resolution computed tomography and pulmonary function measurements during an acute exacerbation in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

An alternate method of classifying allergic bronchopulmonary aspergillosis based on high-attenuation mucus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Assessing response to treatment of exacerbations of bronchiectasis in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Mannose-binding lectin deficiency and respiratory tract infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Impact of mannose-binding lectin insufficiency on the course of cystic fibrosis: A review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Human L-ficolin (ficolin-2) and its clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Matrix metalloproteinase-1 polymorphism (-1607G) and disease severity in non-cystic fibrosis bronchiectasis in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

HLA-C and killer cell immunoglobulin-like receptor genes in idiopathic bronchiectasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Human leucocyte antigen class II association in idiopathic bronchiectasis, a disease of chronic lung infection, implicates a role for adaptive immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Neutrophil apoptosis, proinflammatory mediators and cell counts in bronchiectasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Systemic markers of inflammation in stable bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Symptoms of airway reflux predict exacerbations and quality of life in bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Azithromycin for prevention of exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Azithromycin and the risk of cardiovascular death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Non-cystic fibrosis bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Eight-weekly intravenous antibiotics is beneficial in severe bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Risk Factors for Bronchiectasis in Children with Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Cystic fibrosis: scoring system with thin-section CT

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.896204

10.1586/17476348.2014.896204

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference